18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma

Wieder, Hinrich; Tekin, Gülaçan; Rosenbaum-Krumme, Sandra; Klode, Joachim; Altenbernd, Jens; Bockisch, Andreas; Nagarajah, James

doi:10.3413/nukmed-0584-13-05

Cited by 24 publications

(19 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[19] In a fair quality study ( n = 90) by Wieder et al ., 18 F-FDG PET/CT was associated with sensitivity and specificity of 87% and 93%, respectively, for detection of melanoma recurrence, whereas serum S-100B monitoring alone was not enough to detect disease progression, though serum S-100B measurements along with whole-body 18 F-FDG PET/CT increased its utility. [20]…”

Section: Discussionmentioning

confidence: 99%

Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in restaging and prognosis of recurrent melanoma after curative surgery

et al. 2019

View full text Add to dashboard Cite

Malignant melanoma is a highly aggressive tumor and surgical resection is the primary treatment. However, the chances of recurrence are quite high despite complete resection. The aim of study was to evaluate the 18 F-fluorodeoxyglucose( 18 F-FDG) positron emission tomography–computed tomography (PET/CT) in detection of recurrent melanoma after curative surgery and its prognostic value. Fifty-four melanoma patients (32 women) with prior primary lesion resection were evaluated with 18 F-FDG PET/CT for clinically suspicious recurrent disease. The diagnostic accuracy of 18 F-FDG PET/CT (visual interpretation as well as semi-quantitative parameter) was determined on the basis of subsequent imaging and clinical follow-up. Melanoma-specific survival and risk of progression (hazard ratio [HR]) were assessed using Kaplan–Meier method and Cox regression analysis. 18 F-FDG PET/CT detected recurrent diseases in 36 (66%) patients including distant metastases in 13 patients and second synchronous malignancy in 2 patients. Overall, the sensitivity, specificity, positive predictive value, and negative predictive value of 18 F-FDG PET/CT were 91.2%, 80.0%, 88.6%, and 84.2%, respectively, with area under the curve of 0.86 (95% confidence interval: 0.74–0.97; P < 0.05). Positive 18 F-FDG PET/CT study was associated with a significantly shorter overall survival than negative study (30.8 ± 4.6 vs. 64.5 ± 6.9 months, P < 0.05). Apart from positive 18 F-FDG PET/CT scan, maximum standardized uptake value (SUVmax) >2.7 and combination of both were independently associated with an increased risk of disease progression (HR = 7.72, 21.58, and 11.37, respectively; P < 0.05). 18 F-FDG PET/CT showed enhanced diagnostic performance in patients with suspicious recurrent malignant melanoma leading to appropriate management. FDG positivity along with SUVmax >2.7 provides important prognostic value in predicting the survival outcomes and assessing the risk of disease progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in restaging and prognosis of recurrent melanoma after curative surgery

et al. 2019

View full text Add to dashboard Cite

show abstract

“… 9 , 10 One such marker, S100B, is especially important to monitor because its level is elevated in >90% of MM patients and its protein level correlates directly with poor survival (<1 year) and relapse, and it is especially predictive when used in combination with other diagnostic indicators. 11 − 13 On the other hand, for the few MM patients (5–10%) who have low levels of S100B, the MM vaccine is most effective at providing longer survival times. 14 , 15 …”

mentioning

confidence: 99%

Covalent Small Molecule Inhibitors of Ca²⁺-Bound S100B

et al. 2014

View full text Add to dashboard Cite

Elevated levels of the tumor marker S100B are observed in malignant melanoma, and this EF-hand-containing protein was shown to directly bind wild-type (wt) p53 in a Ca2+-dependent manner, dissociate the p53 tetramer, and inhibit its tumor suppression functions. Likewise, inhibiting S100B with small interfering RNA (siRNAS100B) is sufficient to restore wild-type p53 levels and its downstream gene products and induce the arrest of cell growth and UV-dependent apoptosis in malignant melanoma. Therefore, it is a goal to develop S100B inhibitors (SBiXs) that inhibit the S100B–p53 complex and restore active p53 in this deadly cancer. Using a structure–activity relationship by nuclear magnetic resonance approach (SAR by NMR), three persistent binding pockets are found on S100B, termed sites 1–3. While inhibitors that simultaneously bind sites 2 and 3 are in place, no molecules that simultaneously bind all three persistent sites are available. For this purpose, Cys84 was used in this study as a potential means to bridge sites 1 and 2 because it is located in a small crevice between these two deeper pockets on the protein. Using a fluorescence polarization competition assay, several Cys84-modified S100B complexes were identified and examined further. For five such SBiX–S100B complexes, crystallographic structures confirmed their covalent binding to Cys84 near site 2 and thus present straightforward chemical biology strategies for bridging sites 1 and 3. Importantly, one such compound, SC1982, showed an S100B-dependent death response in assays with WM115 malignant melanoma cells, so it will be particularly useful for the design of SBiX molecules with improved affinity and specificity.

show abstract

“…In 90 patients, compared with serum protein S100B, PET-positive result patients had a significantly higher risk of melanoma-associated death. 89 The authors concluded that PET/CT is therefore superior to the oftenused serum protein S100B. Bastiaanet et al 90 investigated whether standardized uptake value in PET was associated with disease-free survival-based on 80 patients with stage IIIB disease, FDG uptake in tumors was inversely associated with disease-free survival.…”

Section: Pet/ct For Follow-up and Assessment Of Recurrence In Patientmentioning

confidence: 97%

PET/CT, MR, and PET/MR in Lymphoma and Melanoma

Schwenzer

Pfannenberg

2015

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma

Abstract: PET/CT is suitable to confirm or exclude recurrences and can be used to assess the prognosis in melanoma patients. The diagnostic accuracy and the prognostic power is much higher compared to the serum protein S100B.

Cited by 24 publications

References 23 publications

Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in restaging and prognosis of recurrent melanoma after curative surgery

Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in restaging and prognosis of recurrent melanoma after curative surgery

Covalent Small Molecule Inhibitors of Ca²⁺-Bound S100B

PET/CT, MR, and PET/MR in Lymphoma and Melanoma

Contact Info

Product

Resources

About

18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma

Abstract: PET/CT is suitable to confirm or exclude recurrences and can be used to assess the prognosis in melanoma patients. The diagnostic accuracy and the prognostic power is much higher compared to the serum protein S100B.

Cited by 24 publications

References 23 publications

Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in restaging and prognosis of recurrent melanoma after curative surgery

Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in restaging and prognosis of recurrent melanoma after curative surgery

Covalent Small Molecule Inhibitors of Ca2+-Bound S100B

PET/CT, MR, and PET/MR in Lymphoma and Melanoma

Contact Info

Product

Resources

About

Covalent Small Molecule Inhibitors of Ca²⁺-Bound S100B